Roche announced this morning that its head of pharmaceuticals, Bill Anderson, is leaving the company to pursue "other opportunities" after four years in the role. Anderson will be replaced in the ...
After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...
If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...
Late-stage trial data for Roche’s drug against muscle-wasting Elevidys showed positive results after two years of treatment for male patients aged 4 or older with Duchenne muscular dystrophy.
Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate Nonetheless, Roche’s pharma chief Teresa Graham put Itovebi’s peak sales potential at 2 billion Swiss ...
Roche tells Andrew McConaghie that inaccurate reports of its price have distorted the debate. Just as US pharma is once again ... price cuts it offers to the Department of Health bring it down ...
Hosted on MSN1mon
Roche Pharma CEO on obesity drugs: We haven't yet begun to scratch the surface of the innovationsCNBC's Angelica Peebles talks to Roche Pharma CEO Teresa Graham discusses why we're still in the early stages of the obesity drug race. Moss Landing fire: One of the world’s largest battery ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results